



ANNUAL REPORT

Fiscal Year 2017-2018





A Letter from our Executive Director



It seems like it was just a few years ago when a group of us started the UCLA Vine Street Clinic, the only UCLA research clinic east of La Brea Avenue. But that year was 2005, when all of our work fit down just one hallway. The size and scope of our work has grown tremendously and last year we completed our second expansion inside of the clinic, leaving nowhere else for us to grow at the current location. So this year, with the support of leadership in the Department of Family Medicine, we focused on the outside. With new paint, new window glass, new shutters, new planters and a new security guard, the place is handsome as well as safe and conveniently located for our participants.

Through this growth, CBAM investigators continued projects in other locations. There is a solid line of clinical trials work conducted at the UCLA Family Health Center and more recently at the UCLA Medical Center in Santa Monica. A tremendous amount of administrative, research, training and even some clinical services are conducted at the Family Medicine suite in the Oppenheimer Tower. We continue to provide clinical services to the UCLA Athletics Department on-campus. And it must be mentioned that our CBAM scientists have important work and teaching in far-flung places like Czech Republic, South Africa and Vietnam.

It's my greatest privilege to lead CBAM. And in my reflection, I think it's also fitting that the front of this year's Annual Report features the faces of CBAM scientists, staff, clinicians (and our mascot Gus!). It is so clear that WE are our greatest strength. Even as Gus and I are aging (we both have a lot more grey hair), we continue to take leadership locally, state-wide, nationally and internationally. As a group, we set the bar high in science and in treatment to ensure that people who often are neglected or get substandard care are provided opportunities for participating in science and in cutting-edge treatments. Our flagship services will always be grounded in delivering research and treatment opportunities for people living with addictions and with HIV or who are at risk for HIV. What a great group. What an outstanding mission.

It is my deepest wish that we as a group continue to have good health, cutting edge ideas, fully funded projects, and high-impact papers that change our world and the way services and research are provided in our multiple fields.

A handwritten signature in black ink, appearing to be 'S. S. S.' followed by a flourish.



About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

Key Performance Indicators



2,746 Research visits across multiple sites (an increase of more than 30%)



3,538 Outpatient visits for behavioral therapy and medication-assisted treatment for addiction (an increase of 9%)



\$7.5million in funding for research, training and clinical services



40 Full and part-time employees on our team



41 Peer-reviewed manuscripts published



1,979 people attended meetings or trainings sponsored or co-sponsored by CBAM



1,626 HIV tests performed as part of research visits



3,374 STI tests performed as part of research visits



Research Highlights

mSTUDY Cohort Renewed for Another 5 Years!


This was an exciting year for our cohort study as we reached our initial enrollment goal and were awarded an additional five years of funding from the National Institute on Drug Abuse. This allows us to continue collecting clinical and behavioral data on more than 500 men who have sex with men in order to better understand the effects of substance use on the acquisition and progression of HIV.




Ongoing Clinical Trials

This year saw the continuation of four important clinical trials.

POMA - This inpatient trial examines the medication pomaglumetad methionil (POMA) to determine if it is safe and tolerable when used with methamphetamine. Enrollment in this Phase I study began this past year in Santa Monica and is expected to continue into 2020. Participation in the trial includes a hospital stay for approximately ten nights, in addition to outpatient visits.



ADAPT 2 - This Phase 2 study tests a combination of medications to treat methamphetamine dependence in an outpatient setting. As part of the NIDA-funded Clinical Trials Network, the UCLA Vine Street Clinic is one of several sites conducting the trial, where we lead the network in key performance measures including high rates of recruitment, retention, and data accuracy. Participants come to the clinic twice per week to complete assessments and medical visits.



HPTN 085 (AMP) - We successfully reached full enrollment in the AMP study this year! Active participants will continue into the next year as we complete evaluation of the safety, tolerability, and efficacy of the VRC01 antibody in preventing HIV-1 infection in healthy adults at high risk. This was our first antibody study at the UCLA Vine Street Clinic and we are excited to have been chosen as a site for a new antibody trial to be rolled out in the coming year.



HPTN 083 (CAB) - All continues to go well in this trial of a long-acting medication for the prevention of HIV transmission. The UCLA Vine Street Clinic is one of 45 sites around the world participating in the trial. We received honorable mention at this year's HIV Prevention Trials Network annual meeting for exceeding the targets for enrollment of transgender participants into the study!





New Foundation Funding

We received a grant of \$102,472 from the [California Community Foundation](#) to use data from our mSTUDY cohort to look at the links between mental health and biological predictors of health outcomes in a cohort of primarily minority men who have sex with men (MSM). This is a population with low rates of viral suppression, a key measure of health outcomes for those affected by HIV. Viral suppression is an indicator, not only of overall health, but of transmission risk as those who are virally suppressed present a negligible risk of transmitting HIV to another person. For this reason, ensuring that HIV-positive people are able to achieve viral suppression is important for both the HIV-positive and HIV-negative communities. Findings from this project will expand the base of evidence that informs policy makers of how best to allocate their resources.



Substance Use Measure Identification (SUMI) Tool Launched

This year saw the launch of the free Substance Use Measure Identification tool, developed by the HPTN Substance Users Scientific Committee, co-led by Dr. Shoptaw. This web-based, interactive tool assists researchers around the world in identifying the proper measures and behavioral tools to assess substance use in the setting of HIV. Based on the parameters entered by the user, the tool will list appropriate survey instruments relevant to particular substance use domains that the user plans to measure. The tool can be accessed [here](#).



Lab Recognition at Annual Meeting



The UCLA Vine Street Clinic's lab team received the **LeTanya Johnson-Lewis Award** at the HIV Prevention Trials Network Annual meeting in May. The award recognizes outstanding achievements in clinical lab science and in support of medical technologies. We are exceedingly proud of our staff for their dedication to our patients and their commitment to the highest quality work.

Research Visits

This year saw a 38% jump in the number of research visits at CBAM! That includes work across eight unique studies from clinical trials to behavioral research projects carried out at the UCLA Vine Street Clinic, UCLA Family Health Center and the UCLA Medical Center in Santa Monica.





This was an exciting year for our CHIPTS grant. In October, we announced the new Co-Chairs for our Community Advisory Board (CAB) along with several new members. The CAB works to ensure that the research, dissemination, and other activities conducted by CHIPTS researchers are relevant and meaningful to the lives of the diverse communities we serve. In addition, we brought on new members to the Scientific Advisory Board (SAB), including several international experts who are leaders in their respective fields. The new membership has invigorated our researchers by bringing in new perspectives and fresh energy.

Our 2018 HIV Next Generation Conference (Next Gen) was a great success, attended by 128 faculty, students and community members. After introductions and a plenary by CHIPTS leadership, we heard oral presentations from six trainees, a community panel, staff from the LA County Division on HIV & STD Programs (DHSP) and other CHIPTS faculty and affiliates. In addition, thirteen trainees participated in an afternoon poster session. At the end of the day, attendees voted to award doctoral student Sid Jordan the best scientific oral presentation for his work on "Gender Diversity in Prevention: Findings from the Transmasculine Sexual Health and Reproductive Justice Survey" and undergraduate researcher Joshua Cohen received the best poster award for "Relationships Between Substance Use, Nicotine Use, and HIV in Ethnic MSM."



In May, we co-hosted a conference on HIV & Stigma with the City of LA AIDS Coordinator's Office, Children's Hospital LA, the East LA Women's Center, LA County Commission on HIV, LA Center for Alcohol and Drug Abuse, Next-Level Consulting, and LA Region Pacific AIDS Education and Training Center. Presenters discussed the definition of stigma and its many forms and described ways in which stigma can be addressed at the client, provider, community, and policy level.



CHIPTS awarded funding to young investigators for several pilot studies this year, including:

CHIPTS awarded funding to young investigators for several pilot studies this year, including:



2017 Pilot Studies

<u>Investigator</u>	<u>Study Title</u>
Ryan Cook, MSPH, Doctoral Student	Changes in the microbiome due to HIV infection: What do substance use and obesity have to do with it?
Chunqing Lin PhD	Integrated Psychoactive Substance Use and Mental Health Service for Men Who Have Sex with Men in China
Janine M. Trevillyan, MBBS, FRACP, PhD	Impact of Methamphetamine use and HIV infection on Cardiovascular Risk

For more information on CHIPTS, visit their [website](#).



Publications

CBAM faculty and staff contributed to the publication of 41 peer-reviewed articles in scientific journals. Highlights include results from an outpatient trial of Varenicline for the treatment of methamphetamine (MA) dependence published in *Drug and Alcohol Dependence*. The study found that participants who were given Varenicline, who were able to obtain abstinence at any point in the trial, were less likely to relapse.

Findings from another study were published in the *Journal of Acquired Immune Deficiency Syndromes* showing, not surprisingly, that research participants in HIV Prevention Trials Network Study 061 who remained HIV negative, had higher proportions of social network members, suggesting that an increase in social supports can be protective against HIV acquisition.

We could also be found in the *International Journal of STD and AIDS* this year where we published study findings indicating that preexisting HIV/AIDS conspiracy beliefs may deter some black MSM from adopting PrEP (PreExposure Prophylaxis). We suggest strategies that can be used to address the influence that HIV/AIDS conspiracy beliefs may have on this population, which is disproportionately affected by HIV/AIDS.

Additional articles were published in *American Journal of Drug and Alcohol Abuse*, *Journal of Men's Health*, *Progress in Brain Research*, and *JAMA Internal Medicine* to name a few. To learn more and to read summaries of each article, visit our [website](#).



Website Updates

If you visited our website in 2018, you may have noticed some changes. The site has been updated for easier navigation and a more mobile-friendly format. It's easier than ever to read the latest news, to find a research study to participate in, or to make a donation. Visit us at cbam.ucla.edu!





Training

CBAM is dedicated to training future researchers.



Dr. Emeka Okafor received his PhD in Epidemiology from the University of Florida in 2016. His research focuses on the biological mechanisms that link substance abuse with HIV acquisition, transmission, and disease progression. He is also an HIV Prevention Trials Network Scholar and leads a project to enhance enrollment and retention in HIV clinical trials. This is his second year working with our team.

New to CBAM this year is Dr. Michael Li, who earned his Ph.D. in Preventive Medicine/Health Behavior Research in 2017 from the University of Southern California. He is currently studying the associations between pro-inflammatory markers and minority stress and substance use. He works closely with our clinic staff on a large cohort study and mentors undergraduate students.



We continue to host an intern from the NIDA Summer Research Program for underrepresented undergraduate students. CBAM has been participating in this program for nearly a decade. This year's student, Keenan Ramsey, came to us from the Tulane University, School of Public Health and Tropical Medicine. She spent the summer working on data from one of our methamphetamine studies.

In addition to direct one-on-one mentorship, our Social Media Evaluation and Technical Assistance Center (ETAC) continued to collect extensive longitudinal quantitative data this year. This included participant, costing and intervention exposure data, which will be used to evaluate the effectiveness of ten demonstration sites across the country that are using mobile technology and social media to engage and retain HIV-positive youth and young adults in medical care and help them achieve viral suppression. More information on the project can be found [here](#).




As so often happens, our clinical and training objectives overlapped this year as Dr. Heinzerling served as one of several experts engaged by the TAPC program (Treating Addiction in the Primary Care Safety Net) to provide direct coaching assistance to participating health centers. Program highlights included a shift in perspective about addiction and the use of medication assisted therapy (MAT), as well as an increase in the number of patients receiving treatment at participating clinics. Results of the project were published by the Center for Care Innovations. Click [here](#) to learn more.





Clinical Services

CBAM's clinical services continue to grow with a record 3,538 visits (encounters) this past year. That includes addiction, behavioral and psychiatric services. Our largest service location continues to be the UCLA Family Health Center, our Department's primary care clinic located in Santa Monica. However, CBAM clinicians are in high demand, working closely with other departments at UCLA to provide services across four additional locations.



Dr. Keith Heinzerling was quoted in the Fall 2017 volume of UCLA Health's *Vital Signs*. The article, "Non-Narcotic Approaches to Chronic Pain", discusses how UCLA is proactively responding to the CDC's updated guidelines regarding the prescription of narcotics for noncancer pain. Dr. Heinzerling provides a key perspective as an addiction medicine specialist. The full article can be found [here!](#)

International Reach

Dr. Steve Shoptaw traveled to Vietnam again in the Fall of 2017 to conduct a workshop with our colleagues in the Fogarty International Center's UCLA/Vietnam Training Program in Evaluation & Advanced Methodologies. His presentations, "Medications for Substance Abuse in the Setting of HIV" and "Behavioral Interventions for Substance Abuse in the Setting of HIV" provided key information to our collaborators in Vietnam to increase their capacity to provide services that are influenced by the high-impact science being conducted at UCLA. In the Spring, Dr. Giang Minh Le, Chair of the Dept. of Global Health and Head of the Office of Science & Technology at Hanoi Medical University was back at UCLA working with the faculty and discussing progress. He also gave a guest lecture "Addressing Opioid Addiction in Vietnam: Successes and Challenges".



And in South Africa, we completed enrollment in our first study with the University of Cape Town (UCT). The project compared fMRI images from methamphetamine-dependent individuals using a high-value contingency management (CM) program. Data analysis is currently underway and preliminary findings are exciting! We expect to have several papers published from this first-of-it's-kind study in the coming year. We have already begun planning new projects with our UCT collaborators including submission of an application to fund a project to help people living with HIV/AIDS quit smoking.





CENTER FOR BEHAVIORAL & ADDICTION MEDICINE
 Financial Statement for Fiscal Year 2017/2018
 (July 1, 2017 through June 30, 2018)

INCOME	<u>Permanently Restricted</u>	<u>Temporarily Restricted</u>	<u>Unrestricted</u>	<u>Total</u>	<u>FY 2016/2017</u>
Federal Contracts & Grants	\$ 6,354,482	\$ -	\$ -	\$ 6,354,482	\$ 5,352,889
State/Local Contracts & Grants	\$ -	\$ -	\$ -	\$ -	\$ -
Subcontracts	\$ 201,952	\$ -	\$ -	\$ 201,952	\$ 193,514
Corporations	\$ -	\$ -	\$ -	\$ -	\$ -
Foundations	\$ 74,312	\$ -	\$ -	\$ 74,312	\$ -
Individuals	\$ -	\$ -	\$ -	\$ -	\$ -
UC Funds	\$ -	\$ -	\$ 60,893	\$ 60,893	\$ 132,647
Clinical Services Income	\$ -	\$ 803,920	\$ -	\$ 803,920	\$ 659,234
 TOTAL INCOME	 \$ 6,630,746	 \$ 803,920	 \$ 60,893	 \$ 7,495,559	 \$ 6,338,284
 EXPENSES					
Academic Salaries				\$ 703,491	\$ 695,775
Staff Salaries				\$ 1,720,896	\$ 1,271,681
Fringe Benefits				\$ 1,085,347	\$ 828,404
Stipends - Postdoctoral Fellows				\$ 53,668	\$ -
Stipends - Interns				\$ 3,130	\$ 5,780
Consultants/Guest Lecturers				\$ 18,475	\$ 42,045
Tuition - Postdoctoral Fellows				\$ -	\$ -
Employee Training/Certifications/Licenses/Memberships				\$ 4,632	\$ 2,308
Subawards				\$ 135,286	\$ 64,226
Funds Transferred to Other Departments (Direct)				\$ 907,683	\$ 238,057
Space Rental				\$ 171,555	\$ 170,729
Alterations/Renovations				\$ 48,637	\$ 72,198
Communications				\$ 48,872	\$ 37,487
Clinic Operations				\$ 37,023	\$ 35,270
General Supplies & Equipment				\$ 4,106	\$ 3,759
Computers, Software & Computer Supplies				\$ 40,302	\$ 32,643
Medical Supplies				\$ 46,111	\$ 48,530
Project-Related Supplies				\$ 49,196	\$ 31,865
Travel and Events				\$ 117,863	\$ 110,277
Postage/Courier				\$ 42,198	\$ 19,805
Print/Copy Services				\$ 4,011	\$ 835
Recruitment Ads				\$ 111,504	\$ 75,569
Lab Services				\$ 153,946	\$ 68,519
Pharmacy				\$ 73,627	\$ 45,070
Inpatient Care				\$ 121,685	\$ -
Participant Incentives				\$ 176,965	\$ 103,910
Miscellaneous				\$ 1,737	\$ 5,611
Indirect Charges				\$ 1,430,147	\$ 814,262
 TOTAL EXPENSES				 \$ 7,312,092	 \$ 4,824,616
 NET INCOME (LOSS) YTD*				 \$ 183,467	 \$ 1,513,668

This document was generated internally. It is not an audited financial statement.

**The net balance is primarily restricted project funding that will carryover into the next fiscal year.*



Our Impact

CBAM is unique in that we bring research directly into communities where the need is greatest. We are continually amazed by the strength and resilience of our research participants. Change is difficult, especially for those without strong support systems and significant resources. We are humbled to share the quote below from one participant who was able to make some big life changes this year.

I wanted to thank you all for providing this study and allowing me to participate. I was stuck in a very dark time in my life when I began this study, but participating has given me the opportunity to recognize, and change, some of my harmful and reckless behaviors. I've made some drastic changes to my life since I began the study and I'm now much further along my journey towards recovery. I'm very grateful for the UCLA research team and the Vine Street Clinic Staff for their work and support. Thank you for everything!

Show your support!

To help support this life-changing work, visit us at <http://www.uclacbam.org/about-us/donate/> or call (310) 794-0645 to speak with our Administrative Director. More than 90% of every donation goes directly to serve our mission and all donations are tax deductible. Naming opportunities are available!

